Grannus Therapeutics is a biotechnology company that focuses on the development of small molecule inhibitors for specific isoforms of HSP90.
Grannus Therapeutics has raised $800K in total funding. The most recent round was Debt Financing. The last funding was announced in January 2024.
Grannus Therapeutics's investors include Elevate Ventures.
Grannus Therapeutics is headquartered in Indianapolis, United States.
Grannus Therapeutics is a biotechnology company that focuses on the development of small molecule inhibitors for specific isoforms of HSP90.
Grannus Therapeutics is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Grannus Therapeutics — Funding & Investors." VCBacked, January 11, 2024, https://www.vcbacked.co/company/grannus-therapeutics. Accessed September 15, 2026.
VCBacked. (2024). Grannus Therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/grannus-therapeutics
{{cite web |title=Grannus Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/grannus-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated